J. Lipid Res. Did you know there is a large type edition? Click here.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

A more recent version of this article appeared on March 1, 2008

Papers In Press, published online ahead of print December 12, 2007
J. Lipid Res., doi:10.1194/jlr.M700525-JLR200
This Article
Right arrow Full Text (Accepted Manuscript)
Right arrow All Versions of this Article:
M700525-JLR200v1
49/3/663    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, B.
Right arrow Articles by Dietschy, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, B.
Right arrow Articles by Dietschy, J. M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Submitted on November 15, 2007
Revised on December 5, 2007
Accepted on December 12, 2007

Genetic variations and treatments that affect the lifespan of the NPC1 mouse

Benny Liu, Hao Li, Joyce J. Repa, Stephen D. Turley, and John M. Dietschy

Internal Medicine, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390-8887

Corresponding Author: john.dietschy{at}utsouthwestern.edu

Niemann-Pick type C disease is a multisystem disorder caused primarily by a mutation in the npc1 gene. These studies evaluated the effect of genetic background, deletion of additional genes, and administration of several agents on the age at death in a murine model of this disorder. Such factors as differing strain background or genetic drift within a given background in the npc1-/- mouse significantly altered the age at death and the degree of organ disease. Genetic deletion of Siat9 (GM3 synthetase) or Nr1h2 (LXRß) shortened the life of the npc1-/- animals. Daily treatment of the npc1-/- mice with an LXR agonist or the administration of a single dose of cyclodextrin, with or without the neurosteroid allopregnanolone, significantly slowed neurodegeneration and increased the lifespan of these animals. These data illustrate that the age at death of the npc1-/- mouse can be significantly influenced by many factors including differences in strain background, other inactivating gene mutations (Siat9 and lxrß), and administration of agents such as LXR agonists and, particularly, cyclodextrin. It is currently not clear which of these effects is non-specific or which might relate directly to the molecular defect present in the NPC1 syndrome.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 JRSMHome page
S. Green
Medical progress depends on animal models - doesn't it?
J R Soc Med, May 1, 2008; 101(5): 220 - 221.
[Full Text] [PDF]

Home page
 J. Lipid Res.Home page
S. K. Erickson
Genes, environment, and lifespan: new insights into Niemann-Pick C disease
J. Lipid Res., March 1, 2008; 49(3): 497 - 498.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Copyright © 2007 by the American Society for Biochemistry and Molecular Biology.